August 28, 2018 07:00 AM EDTUpdated 08:52 AM
People
Financing

Vivek Ra­maswamy bags $100M in risk cap­i­tal to back his lat­est PhI­II gam­ble at Der­ma­vant — while Urovant dives in­to gene ther­a­py

John Carroll

Editor & Founder

Just a few days af­ter clos­ing on a $330 mil­lion deal with Glax­o­SmithK­line to reel in a Phase III-ready drug for the crowd­ed R …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times